Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Diabetologia. 2019 Jan 9;62(4):676–686. doi: 10.1007/s00125-018-4802-0

Fig. 3.

Fig. 3

Mct1 and Mct2 mRNA levels in the VMH. (a) In comparison with the control group (n=8), Mct1 mRNA level in the VMH was not significantly altered by recurrent hypoglycaemia (n=9). Treatment of recurrently hypoglycaemic (RH) rats with carvedilol (n=8) reduced the Mct1 mRNA levels slightly, although the difference just failed to reach statistical significance (p=0.09 vs RH). (b) Mct2 mRNA expression in the VMH was significantly upregulated in RH animals (n=8) compared with controls (n=8) (*p<0.05 vs control); treatment with carvedilol (n=7) restored these levels to normal (**p<0.01 vs RH). Data were analysed using one-way ANOVA with post hoc Tukey honest significant difference (HSD) test and presented as mean ± SEM. RH, recurrently hypoglycaemic